Jacqueline A M Smith - Revolution Medicines (United States)

Yu C. Yang, Severin Thompson, David Montgomery, Antonio J. Quinones, Xing Wei, Benjamin Madej, Aidan Tomlinson, Nataliya T. Shifrin, Alexander McNamara, Ethan Ahler,Laura L. McDowell, Michael Flagella,

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRAS^G12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models

Marie J. Menard, Christopher Chow,Kevin Chen,Cristina Blaj, Nataliya Tovbis Shifrin, Haley Courtney, Nicole M. Nasholm, Anna Pham,Alice Kumamoto, Swetha Ganesh,James W. Evans, Lindsey Lawrence,

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

RMC-9805, a first-in-class, mutant-selective, covalent and oral KRAS^G12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRAS^G12D cancers

Lingyan Jiang, Marie Menard, Caroline Weller,Zhican Wang, Les Burnett, Ida Aronchik, Shelby Steele, Mike Flagella, Ruiping Zhao, James W. W. Evans, Shook Chin, Kang-Jye Chou,

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

Abstract 1598: RM-046, a first-in-class, mutant-selective, and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target

Yu Chi Yang, Severin K. Thompson, David Montgomery, Antonio J. Quiñones, Xing Wang, Benjamin D. Madej, Aidan Tomlinson, Nataliya Shifrin, Alexander McNamara, Ethan Ahler,Laura McDowell, Michael Flagella,

Cancer Researchno. 7_Supplement (2023): 1598-1598

引用0浏览0引用

Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression